Inclusion Criteria:  Adults (18 years or older).  Body weight ≥ 60 kg. Diagnosis of chronic kidney disease on hemodialysis, clinically stable (with a minimum of 3 months of treatment) and nonvalvular atrial fibrillation in treatment with coumarins. Patient candidate for change of anticoagulant treatment. In women of childbearing age, negative pregnancy test (negative human coriogonadotropine (hCG) urine test). The subject gives informed consent.  Exclusion Criteria:  • Pregnant or lactating women.  Women of childbearing age (period of time from menarche to postmenopausal status, defined as 12 months absence of menstruation without other medical cause) who do not follow the contraceptive methods recommended by the Clinical Trial Facilitation Group (CTFG) (https://www.hma.eu/fileadm/dateien/Human_Medicines/01): Hormonal contraceptives associated with ovulation inhibitors, intrauterine devices, surgical methods (tubal ligation, vasectomy), abstinence, and barrier methods. Body weight ≤ 60 kg. Presence of liver disease (patients with elevated liver enzyme levels alanine aminotransferase (ALT) / aspartate aminotransferase (AST)> 2x the upper limit of normal, or total bilirubin> 1.5 ULN). Thrombopenia (<100.000 platelets/mL). Be on treatment with other anticoagulants (heparins) or antiplatelet drugs. Be treated with enzyme inhibitors (such as azole antifungals or HIV protease inhibitors) or enzyme inducers (such as rifampin, phenobarbital, carbamazepine, or phenytoin) of CYP3A4 (Cytochrome P450 3A4 oxidase ). History of bleeding episode in the last month. Presence of clinical or analytical alterations not attributable to the stage of kidney disease Participation in another clinical trial of pharmacological treatment.